- Home
- VTYX vs FBRX Comparison
VTYX vs FBRX Comparison
Compare VTYX & FBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTYX
- FBRX
- Stock Information
- Founded
- VTYX 2018
- FBRX N/A
- Country
- VTYX United States
- FBRX United States
- Employees
- VTYX N/A
- FBRX N/A
- Industry
- VTYX Medicinal Chemicals and Botanical Products
- FBRX Biotechnology: Pharmaceutical Preparations
- Sector
- VTYX Health Care
- FBRX Health Care
- Exchange
- VTYX Nasdaq
- FBRX Nasdaq
- Market Cap
- VTYX 154.9M
- FBRX 154.5M
- IPO Year
- VTYX 2021
- FBRX N/A
- Fundamental
- Price
- VTYX $2.74
- FBRX $11.43
- Analyst Decision
- VTYX Buy
- FBRX Strong Buy
- Analyst Count
- VTYX 2
- FBRX 3
- Target Price
- VTYX $9.00
- FBRX $68.00
- AVG Volume (30 Days)
- VTYX 776.8K
- FBRX 59.5K
- Earning Date
- VTYX 08-07-2025
- FBRX 08-14-2025
- Dividend Yield
- VTYX N/A
- FBRX N/A
- EPS Growth
- VTYX N/A
- FBRX N/A
- EPS
- VTYX N/A
- FBRX N/A
- Revenue
- VTYX N/A
- FBRX N/A
- Revenue This Year
- VTYX N/A
- FBRX N/A
- Revenue Next Year
- VTYX N/A
- FBRX N/A
- P/E Ratio
- VTYX N/A
- FBRX N/A
- Revenue Growth
- VTYX N/A
- FBRX N/A
- 52 Week Low
- VTYX $0.78
- FBRX $4.11
- 52 Week High
- VTYX $3.39
- FBRX $28.68
- Technical
- Relative Strength Index (RSI)
- VTYX 51.07
- FBRX 54.64
- Support Level
- VTYX $2.38
- FBRX $9.91
- Resistance Level
- VTYX $3.05
- FBRX $13.63
- Average True Range (ATR)
- VTYX 0.22
- FBRX 0.92
- MACD
- VTYX -0.02
- FBRX 0.14
- Stochastic Oscillator
- VTYX 55.15
- FBRX 51.43
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.
About FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, alopecia areata, and type 1 diabetes (T1D).